Are cytokine gene polymorphisms associated with outcome in patients with idiopathic intermediate uveitis in the United Kingdom?

M R Stanford, R W Vaughan, E Kondeatis, Y Chen, C E Edelsten, E M Graham, G R Wallace

Background/aim: Competing levels of cytokines, either locally within the eye or systemically, may influence the eventual outcome of ocular inflammation. Polymorphism in the promoter part of the genes controlling cytokine production may result in either higher or lower production of the relevant cytokine to a given stimulus. The authors hypothesised that such polymorphisms may relate to visual outcome in patients with idiopathic intermediate uveitis.

Methods: DNA was obtained from 125 patients with idiopathic intermediate uveitis and analysed for the interleukin 10 IL-10–1082G/A and IL-10–819C/T, and interferon γ IFNγ 874T/A gene polymorphisms. Associations with disease were calculated by both allelic frequency and haplotype analysis, and associations between ocular disease outcomes and the presence of polymorphisms were identified. A bad outcome was defined as loss of vision < 6/12 Snellen in both eyes at 5 years from presentation when the eyes were quiet.

Results: An initial screen showed that the 874T allele of the IFNγ gene was more prevalent in patients than controls ($\chi^2$ = 7.9; p = 0.004 OR 1.7; 95% CI 1.2 to 2.6 (Pc = 0.02), whereas the IL-10-1082/−819 AT haplotype of the interleukin 10 (IL-10) gene was not. Analysis of disease outcome showed an association between IL-10-1082 AA homozygosity and bad outcome ($\chi^2$ = 13; p = 0.0003). Moreover, the two cytokine polymorphisms taken together showed that up to 75% of patients with a poor visual outcome had the combined IFNγ 874TA or TT genotype together with the IL-10-1082AA genotype ($\chi^2$ = 13.2 p = 0.0008 OR 6.4; 95% CI 1.85 to 23.6 (Pc = 0.1)).

Conclusion: These results show that disease outcome in intermediate uveitis may be partly determined by a complex interplay between cytokine genes and these results may have implications for future treatment with biological agents that target these cytokines.

Intermediate uveitis is one of a number of sight threatening inflammatory diseases characterised by breakdown of the blood-retinal barrier with leucocytic infiltration of the retina and macular oedema. It has a variety of clinical presentations, systemic disease associations, and long term effects on visual function. Intermediate uveitis is classically linked to multiple sclerosis and sarcoidosis but may be idiopathic where there is no association with inflammatory disease outside of the eye. Intermediate uveitis is generally considered to be an autoimmune, cell mediated, organ disease outside of the eye. Intermediate uveitis is generally considered to be an autoimmune, cell mediated, organ disease outside of the eye. Intermediate uveitis is generally considered to be an autoimmune, cell mediated, organ disease outside of the eye. Intermediate uveitis is generally considered to be an autoimmune, cell mediated, organ disease outside of the eye.

It is increasingly apparent that inflammatory reactions can be profoundly influenced by the cytokine milieu in which they occur. For instance, interferon gamma (IFNγ) is associated with a Th1 pro-inflammatory phenotype and has been shown to regulate expression of experimental autoimmune uveitis (EAU). IFNγ production is influenced by polymorphism of a dinucleotide repeat in the promoter part of the IFNγ gene that defines high IFNγ production, and by a single nucleotide polymorphism (SNP) A874T that is in absolute correlation with the repeat. The presence of this SNP confers the ability to produce IFNγ and there is a gene dosage effect so that homozygotes produce more of the cytokine than heterozygotes or those in whom the SNP is not present. The clinical relevance of this finding has been shown in transplantation biology where the presence of IFNγ 874T was associated with the development of allograft inflammation and fibrosis following lung transplantation. Conversely, IL-10 is generally thought to inhibit the synthesis of a variety of pro-inflammatory molecules and downregulate immune responses. Once again, there are three single nucleotide polymorphisms at positions −1082, −819, −592 in the promoter region of the IL-10 gene reported. The ATA haplotype is associated with low IL-10 production and its presence has been linked to severe asthma. There is currently little information available about the possible interaction between these genes in terms of disease outcome, but it is likely that competing levels of pro-inflammatory and anti-inflammatory cytokines will determine the course and outcome in many inflammatory diseases.

We therefore sought to address whether there was an association between the IFNγ 874T and/or the IL-10 AT haplotype with disease or its outcome in intermediate uveitis. We have investigated polymorphism at IL-10 in positions −1082 and −819 only, as in the published data the polymorphism at −819 and −592 are in complete linkage disequilibrium.

MATERIALS AND METHODS

Patients

Following informed consent, blood samples were collected by venepuncture from 125 patients with intermediate uveitis.

Abbreviations: EAU, experimental autoimmune uveitis; IFNγ, interferon gamma; IL-10, interleukin 10; PCR, polymerase chain reaction; SNP, single nucleotide polymorphism
attending the medical eye unit at St Thomas's Hospital, London. Patients with multiple sclerosis, sarcoidosis, Behçet's disease, seronegative arthropathy, inflammatory bowel disease or infectious or neoplastic uveitis at baseline, or who developed these diseases during follow up, were also excluded on the basis of clinical history, systemic examination, and relevant investigations. Patients with Fuchs' heterochromic cyclitis were excluded. All patients had bilateral disease. Healthy race matched individuals attending the clinical transplantation laboratory at Guy’s Hospital, London, \( n = 100 \) provided blood as normal controls. The patients were managed by two senior ophthalmologists with a consistent philosophy to treatment and patient care was shared by the two clinicians throughout follow up. Outcome was defined as bad if the acuity of each eye was <6/12 Snellen in a quiet eye after 5 years. We did not include immunosuppressive treatment as a disease outcome measure since patients may require intensive treatment and still have a good outcome and vice versa. Patients with visual loss for reasons other than intraocular inflammation (for example, cataract, optic neuropathy, or amblyopia) were excluded from analysis.

### DNA extraction and PCR

DNA was prepared by proteinase K digestion, and salt extraction and stored at \(-70\)°C until use. Polymorphism in the promoter region of the IL-10 gene at positions \(-1082\) G/A and \(-819\) C/T were detected by a PCR-SSP assay using four primer mixes.

\(-1082G:\)

5’ CAGTGCAACTTgAATTgg 3’

5’ CTACTAAGggCTCTTTggAg 3’

\(-1082A:\)

5’ CAGTGCAACTTgAAATTgT 3’

5’ ACTACTAAGggCTCTTTggAA 3’

\(-819 C:\)

5’ AggATgTgTTCACCggCTCT 3’

5’ CcCTTgTACggTAgTgTAAC 3’

\((-819T:\)

5’ AggATgTgTTCACCggCTCT 3’

5’ ACCCTTgTACggTAgTgTAAT 3’ sense

The IFN\(\gamma\) A874T polymorphism was also detected by PCR-SSP using two primer mixes taken from Pravica et al.:

874 T:

5’TcTTTACACACAAATCAAACTCT 3’

5’TACACAAAgCTgATACCTCCa 3’

874 A:

5’TcTTTACACACAAATCAAACTCTAC 3’

5’TACACAAAgCTgATACCTCC3’

The final volume of all polymerase chain reaction (PCR) reactions was 10 μl; the PCR reaction mixtures consisted of 67 mM TRIS base pH 8.8, 16.6 mM ammonium sulphate, 2 mM magnesium chloride, 0.01%(v/v) Tween20, 200 μM of each dNTP, 1–4 μM of each allele specific primer, 0.1 μM of control primer, 0.1 μg of DNA, and 0.1875 units of Taq Polymerase (Abgene, Epsom, UK). All reactions were carried out in a Geneamp PCR System 9700 thermal cycler (PE Biosystems, Foster City, CA, USA). PCR cycling conditions consisted of five cycles of 96°C for 25 seconds, 70°C for 45 seconds, and 72°C for 20 seconds, followed by 21 cycles of 96°C for 25 seconds, 70°C for 45 seconds, and 72°C for 45 seconds; and finally four cycles with 96°C for 25 seconds, 70°C for 45 seconds, and 72°C for 120 seconds. The PCR products were visualised by electrophoresis through a 1% agarose gel in 0.5X TBE buffer containing 100 μg/l ethidium bromide. The relative size of the PCR products was determined by comparison of the migration of a 100–1000 bp DNA molecular weight ladder (Abgene, Epsom, UK). A permanent visual image was obtained using a ultraviolet illuminator and a UVP Imagestore 7500 (UVP Products Ltd, Cambridge, UK).

### Analysis of data

Associations with disease were calculated by both allelic frequency and haplotype analysis. Associations between ocular disease outcomes and the presence of polymorphisms were identified by \(\chi^2\) analysis with Yates' correction. Results are expressed as odds ratios (OR) with 95% confidence intervals (95% CI). A Bonferroni correction factor for the number of comparisons made was applied to the IFN\(\gamma\) A874T polymorphism and the complex haplotype analysis with outcome (Pc).

### RESULTS

In all, 125 patients were enrolled in the study; outcome data at 5 years were available for 102 patients; 62% were male with an age range of 21–76 years (mean 42) at last follow up. Of the 102 patients, 33 (33%) had a bad outcome, all of whom showed irreversible macular damage. The definition of good or bad outcome was determined before the genotype study. All the genotypes tested were in Hardy-Weinberg equilibrium between groups and the \(-1082\) haplotype frequency was similar to previous reported studies.\(^*\)

Genotype analysis of the IFN\(\gamma\) gene showed a greater prevalence of the 874T allele in patients compared to controls (54% vs 41% \(\chi^2 = 7.9\) Pc = 0.006 OR 1.7; 95% CI 1.2 to 2.6). This was particularly striking for TT homozygotes, which were more prevalent in the patient group (30% vs 16%, \(\chi^2 = 6.3\) Pc = 0.01 OR 2.3; 95% CI 1.1 to 4.7), with a concomitant decrease in AA homozygotes (table 1).

We then addressed whether there was an association between disease outcome and the 874 SNP. There was a trend

### Table 1 Analysis of the IFN\(\gamma\) A874T polymorphism in patients with intermediate uveitis and healthy controls

<table>
<thead>
<tr>
<th>IFN(\gamma) A874T</th>
<th>Intermediate uveitis patients</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotype</td>
<td>n = 125</td>
<td>n = 100</td>
</tr>
<tr>
<td>TT</td>
<td>38 (30%)*</td>
<td>16</td>
</tr>
<tr>
<td>TA</td>
<td>60 (48%)</td>
<td>50</td>
</tr>
<tr>
<td>AA</td>
<td>27 (22%)</td>
<td>34</td>
</tr>
<tr>
<td>Allele</td>
<td>n = 250</td>
<td>n = 200</td>
</tr>
<tr>
<td>T</td>
<td>136 (54%)†</td>
<td>82 (41%)</td>
</tr>
<tr>
<td>A</td>
<td>114 (46%)</td>
<td>118 (59%)</td>
</tr>
</tbody>
</table>

\(*\chi^2 = 6.3, p = 0.001\) (Yates 0.02) OR 2.3; 95% CI 1.1 to 4.7.

\(\ddagger\chi^2 = 7.9, p = 0.004\) (Yates 0.006) OR 1.7; 95% CI 1.2 to 2.6.

### Table 2 IL-10 haplotype and genotype for patients with intermediate uveitis and healthy controls

<table>
<thead>
<tr>
<th>IL-10 – 1082</th>
<th>Patients (n = 125)</th>
<th>Controls (n = 98)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Haplotype analysis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AT</td>
<td>48 (19%)</td>
<td>48 (24%)</td>
</tr>
<tr>
<td>AC</td>
<td>67 (27%)</td>
<td>51 (26%)</td>
</tr>
<tr>
<td>GC</td>
<td>133 (54%)</td>
<td>97 (50%)</td>
</tr>
</tbody>
</table>

| **Genotype analysis** |                   |
| AT/AT                | 9 (7%)             |
| AT/AC                | 9 (7%)             |
| AC/AC                | 12 (10%)           |
| AT/GC                | 21 (17%)           |
| AC/GC                | 34 (27%)           |
| GC/GC                | 40 (32%)           |

There were no significant differences between any of the groups.

---

\(\text{www.bjophthalmol.com} \)
towards the 874T allele being more prevalent in patients with a bad disease outcome (56% vs 45%; p = 0.5) but this did not reach significance.

The IL-10 haplotype was analysed in the same group of patients. In all cases −1082G was linked to −819C, although −1082A was associated with both −819C and −819T, therefore the GT haplotype was not observed. There was no association with either −1082A alone, the AT haplotype, or any of the −1082 genotypes and disease in patients (table 2). When analysed on the basis of outcome, IL-10−1082AA homoygosity was strongly associated with bad outcome (46% vs 13%; χ² = 13 PC = 0.0003 OR 5.6 95% CI 1.9 to 16.7) (table 3).

We next analysed the two polymorphisms as a complex haplotype. All genotypes of 874 and the AA homoygous −1082 were compared with disease outcome. Of those patients with a bad outcome 57% were AA/AA, 33% AA/TA, and 63% AA/TT compared to 27%, 6%, and 16%, respectively for patients with a good outcome. When those patients with AA −1082/AA 874 genotypes were compared to other −1082/874 genotypes based on outcome, the result was significant (χ² = 13.2 PC = 0.002 OR 5.6 95% CI 1.9 to 16.7) (table 3). However, there was no trend for patients with bad outcome to have IL-10−1082 AA genotype in association with any IFNγ 874T haplotype compared to patients with a good outcome. This was particularly prominent in those patients with 874 TT.

\[
\text{Table 3 Association of IL-10−1082 AA with outcome}
\]

<table>
<thead>
<tr>
<th>Outcome</th>
<th>IL-10−1082 AA</th>
<th>IL-10−1082 AA/IFNγ 874</th>
</tr>
</thead>
<tbody>
<tr>
<td>Good</td>
<td>9/69 (13%)</td>
<td>15/33 (46%)*</td>
</tr>
<tr>
<td>Bad</td>
<td>3/11 (22%)</td>
<td>4/7 (57%)</td>
</tr>
<tr>
<td>AA/AA</td>
<td>2/33 (6%)</td>
<td>6/18 (33%)†</td>
</tr>
<tr>
<td>AA/TT</td>
<td>4/25 (16%)</td>
<td>5/8 (63%)†</td>
</tr>
</tbody>
</table>

*In patients for whom data were available (n = 73) the IL-10−1082AA genotype was more prevalent in those with bad compared to good outcome. When analysed on the basis of IL-10−1082AA and IFNγ 874, those patients expressing 874T were more likely to have had a bad outcome.

+) IL-10−1082 AA versus outcome χ² = 13 p = 0.0003 (Yates 0.0008) OR 5.6 95% CI 1.9 to 16.7.

*+) IFNγ T and IL-10−1082 AA versus outcome χ² = 13.2 p = 0.002 (Yates 0.002) OR 5.6 95% CI 1.9 to 16.7.

\[\text{DISCUSSION}\]

Interferon γ production is the hallmark of a Th1 response and polymorphisms in its gene that result in higher production for a given stimulus might be expected to produce more severe inflammation and tissue destruction. In this study of patients with intermediate uveitis, the IFNγ A874T polymorphism, which reflects a constitutively higher production of IFNγ, was significantly associated with disease and, although not statistically significant, there was a trend towards an association with disease outcome. Although not significant alone, the IL-10−1082AA haplotype was associated with bad outcome when analysed in conjunction with IFNγ 874 haplotypes. In particular, the −1082AA/874TT haplotype that would produce low IL-10 and high IFNγ was present in almost half the −1082 AA patients with bad outcome, compared to only 16% of those with a good outcome. Increased production of IFNγ in patients with intermediate uveitis would induce increased MHC class I and class II expression, intercellular adhesion molecule-1, and inducible nitric oxide synthetase, all of which have been shown to be raised in intermediate uveitis and lead to lymphocyte infiltration and tissue damage. 11–13 By comparison, low IL-10 would lead to a decrease in regulation and a subsequent increase in the Th1 response and thus to more severe disease. 14

The role of cytokines in uveitis is complex. Significant levels of cytokine mRNA and protein were found in cells taken from the aqueous humour of patients with uveitis and indicated a Th1 profile. 15–16 Levels of both IFNγ and IL-10 in the serum were elevated in patients with uveitis, while only IFNγ was raised in aqueous humour samples from patients with uveitis compared to cataract controls. 17 In patients with infectious uveitis, both IFNγ and IL-10 were detected in significantly more aqueous samples and at higher levels compared to control samples. 18 Similarly, in EAU, uveitogenic cells have a Th1 profile and genetic susceptibility to disease induction is associated with an increased Th1 response.19 Paradoxically, neutralisation of IFNγ exacerbated EAU, which may be explained by studies in IFNγ deficient mice challenged with interphotoreceptor binding protein who developed EAU comparable in severity to wild type mice, with an excessive granulocyte infiltration and increased IL-3, IL-6, and IL-10. 20–22 These data demonstrate that IFNγ, in addition to a pathogenic role, has a protective capacity in uveitis. Such competing mechanisms support the complex nature of cytokine interactions in inflammatory disease.

Similarly, IL-10 can influence the inflammatory response at several points. Firstly, in the initial stage of bacterial or viral infections or at sites of tissue damage, IL-10 induces activation of natural killer cells and macrophage phagocytosis. 22 Secondly, as the adaptive immune response develops, IL-10 inhibits Th1 cells and macrophage activation, by inhibition of expression of co-stimulatory molecules and pro-inflammatory cytokines. 23 Thirdly, IL-10 has been shown to be a pivotal mediator of regulatory T cells 24 and the AT haplotype may be associated with reduced numbers or effectiveness of such cells. EAU resistant F344 rats express higher basal levels of IL-10 mRNA in ocular tissue, while susceptible strains have low levels, and it has been suggested that higher expression of the IL-10 gene may contribute to a higher threshold of resistance to EAU. 25 In support of a protective role for IL-10, mice given viral IL-10, that retains immunosuppressive but not immune activation function, before induction of EAU showed less ocular pathology and lower IFNγ and IL-2 production by antigen challenged splenocytes. 26 It should be noted that these mechanisms are controversial in animal models and have not been shown to be active in humans. Moreover, other SNP have been reported in the genes encoding IL-10 and IFNγ that may also influence production of these cytokines. 27–28

A number of potential sources of bias arise concerning our clinical data. Firstly, the study population may have shown a selection bias towards patients with poor outcome. The patient population was derived from a tertiary referral centre and, although patients are followed as a routine for extended periods, those who had mild disease or in whom disease had regressed may have been lost to follow up. Accordingly, only patients with more severe disease may have been included in the analysis. Secondly, since this was a review of case records to determine outcome, it is possible that further improvements in visual acuity after 5 years might have been possible with more aggressive treatment—that is, the best recorded visual acuity at the end of follow up was not necessarily the best possible. However, in all cases, the patients were seen by senior ophthalmologists experienced in the management of intraocular inflammation during the fifth year making this less likely. Furthermore, any bias introduced by inconsistencies in treatment was avoided by recording the acuity when
disease was quiet. Thirdly, the clinical homogeneity of the population studied may be questioned. Although unlikely, it is still possible that patients who only had isolated disease confined to the eye would have developed an associated systemic disease after 5 years. For instance, multiple sclerosis has been reported to occur after 7 years of follow up, and a recent study showed that the mean time from the onset of posterior uveitis to development of multiple sclerosis was 8.5 years.10

Uveitis is mediated by cytokines that may exacerbate or ameliorate disease depending on level and time of production. Of the cytokines in the current study, IFNγ is generally deleterious while IL-10 is protective, and the production of both has been demonstrated to be under genetic control. The results presented here suggest the possibility that a complex haplotype based on low production of IL-10 and high production of IFNγ can be associated with a bad visual outcome in patients with intermediate uveitis. Furthermore, our results may have therapeutic implications since there is considerable interest in using monoclonal antibodies against cytokines in treatment, and the ability to tailor immunoregulatory regimes to a patient’s genetic background would make this more rational. To our knowledge this is the first demonstration of a genetic basis for outcome of intermediate uveitis. While it is clear that other mediators and polymorphisms will be involved in the onset and outcome of disease, these results show that identification of complex genotypes may distinguish, at an early stage those patients likely to progress to severe disease and be treated accordingly.

ACKNOWLEDGEMENTS
This work was supported by the Guide Dogs for the Blind Association and The Iris Fund for the Prevention of Blindness.

Authors’ affiliations
M R Stanford, R Y Chen, E M Graham, G R Wallace, Departments of Ophthalmology, Guy’s, King’s and St Thomas’s Hospital Medical Schools, London, UK
R W Vaughan, E Kondeatis, Clinical Transplantation Laboratory, Guy’s, King’s and St Thomas’s Hospital Medical Schools, London, UK
C E E dedleton, Department of Ophthalmology, Ipswich General Hospital, UK
G R Wallace, Academic Unit of Ophthalmology, University of Birmingham, Birmingham, UK

Competing interests: none declared

This study received ethical approval from the St Thomas’s Research Ethics Committee.

REFERENCES

4 Sun B, Sun SH, Chan CC, et al. Autoimmunity to a pathogenic retinal antigen begins as a balanced cytokine response that polarizes towards type 1 in a disease-susceptible and towards Th2 in a disease-resistant genotype. Int Immunol 1999;11:1307–12
16 Muthaya M, Calder T, Towler HMA, et al. Characterization of T cells and cytokines in the aqueous humour (AH) of patients with Fuch’s heterochromic cyclitis (FHC) and idiopathic anterior uveitis (IAU) Clin Exp Immunol 1998;113:93–8

www.bjophthalmol.com
Are cytokine gene polymorphisms associated with outcome in patients with idiopathic intermediate uveitis in the United Kingdom?

M R Stanford, R W Vaughan, E Kondeatis, Y Chen, C E Edelsten, E M Graham and G R Wallace

Br J Ophthalmol 2005 89: 1013-1016
doi: 10.1136/bjo.2004.057620